<DOC>
	<DOCNO>NCT02015013</DOCNO>
	<brief_summary>Idiopathic CD4 lymphocytopenia ( ICL ) rare syndrome define consistently low CD4 T cell count ( &lt; 300/mm3 ) without evidence HIV infection know immunodeficiency . Patients ICL risk opportunistic infection typically associated HIV/AIDS disseminate cryptococcal infection severe human papillomavirus-related dysplasia . More 20 year since description ICL , etiology , pathogenesis , management remain unclear . In study propose administer combination granulocyte colony stimulate factor ( G-CSF ) plerixafor ICL patient healthy volunteer objective harvest mobilize CD34+ hematopoietic progenitor cell ( HPCs ) apheresis transfer immunocompromised mouse study vitro assay . The mouse study would serve investigate thymic development , survival , traffic mobilize human cell within murine lymphoid non-lymphoid organ . HPCs use various therapy increase use agent stimulate bone marrow produce progenitor cell move bloodstream may harvest apheresis . Not patient respond GCSF vigorous HPC mobilization . The bind chemokine receptor CXCR4 stromal cell derive factor ( SDF-1 CXCL12 ) important interaction hematopoietic progenitor cell marrow environment . Plerixafor CXCR4 inhibitor block bind SDF-1 result release hematopoietic progenitor cell ( CD34+ ) peripheral circulation . In pharmacodynamic study plerixafor conjunction G-CSF compare G-CSF placebo , two-fold increase CD34+ cell count observe . Due important role CXCR4 play immune cell traffic potential role pathogenesis ICL , propose secondary objective ass peripheral CD4 T cell CD34+ hematopoietic progenitor cell number function ICL patient compare control follow G-CSF plerixafor administration . Study participant screen within 12 week prior study period . Eligible participant receive G-CSF 5 day hospitalization Day 4 plerixafor injection follow apheresis Day 5 . Participants return examination blood draws Days 8 12 .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Mobilization Idiopathic CD4 Lymphocytopenia Patients Healthy Controls Study T Cell Maturation Trafficking Murine Models</brief_title>
	<detailed_description>Idiopathic CD4 lymphocytopenia ( ICL ) rare syndrome define consistently low CD4 T cell count ( &lt; 300/mm3 ) without evidence HIV infection know immunodeficiency . Patients ICL risk opportunistic infection typically associated HIV/AIDS disseminate cryptococcal infection severe human papillomavirus-related dysplasia . More 20 year since description ICL , etiology , pathogenesis , management remain unclear . In study propose administer combination granulocyte colony stimulate factor ( G-CSF ) plerixafor ICL patient healthy volunteer objective harvest mobilize CD34+ hematopoietic progenitor cell ( HPCs ) apheresis transfer immunocompromised mouse study vitro assay . The mouse study would serve investigate thymic development , survival , traffic mobilize human cell within murine lymphoid non-lymphoid organ . HPCs use various therapy increase use agent stimulate bone marrow produce progenitor cell move bloodstream may harvest apheresis . Not patient respond GCSF vigorous HPC mobilization . The bind chemokine receptor CXCR4 stromal cell derive factor ( SDF-1 CXCL12 ) important interaction hematopoietic progenitor cell marrow environment . Plerixafor CXCR4 inhibitor block bind SDF-1 result release hematopoietic progenitor cell ( CD34+ ) peripheral circulation . In pharmacodynamic study plerixafor conjunction G-CSF compare G-CSF placebo , two-fold increase CD34+ cell count observe . Due important role CXCR4 play immune cell traffic potential role pathogenesis ICL , propose secondary objective ass peripheral CD4 T cell CD34+ hematopoietic progenitor cell number function ICL patient compare control follow G-CSF plerixafor administration . Study participant screen within 12 week prior study period . Eligible participant receive G-CSF 5 day hospitalization Day 4 plerixafor injection follow apheresis Day 5 . Participants return examination blood draws Days 8 12 .</detailed_description>
	<mesh_term>Lymphopenia</mesh_term>
	<mesh_term>T-Lymphocytopenia , Idiopathic CD4-Positive</mesh_term>
	<criteria>INCLUSION CRITERIA ICL patient : 1 . Documented history idiopathic CD4 lymphocytopenia define CD4 T cell count &lt; 300 cells/microL &lt; 20 % total T lymphocytes 2 occasion least 6 week apart absence illness medication account CD4 lymphocytopenia . Although protocol primarily enroll ICL patient lymphopenic time enrollment , three patient clear documentation ICL past currently lymphopenic may still enrol comparative purpose . 2 . Hemoglobin great equal 9 g/dL 3 . Human Tlymphotropic virus Type 1 ( HTLV1 ) HTLV2 seronegative Healthy volunteer : white blood cell count &gt; 2500/mm ( 3 ) hemoglobin great equal 12.5 g/dL ICL patient healthy volunteer : 1 . Age 1865 year 2 . Weight least 50 kg less 167 kg &lt; 175 % ideal body weight ( due lack data regard appropriate dosing plerixafor ) 3 . Ability give inform consent 4 . Capacity willingness adhere study procedure , include schedule followup visit 5 . Willingness blood sample store future research 6 . Willingness undergo genetic test 7 . Willingness hospitalize approximately 24 hour 8 . Established primary care provider 9 . HIV1 HIV2 seronegativity plasma HIV1 RNA PCR limit detection 10 . Adequate venous access allow leukapheresis without use central line 11 . Participant agree heterosexually inactive consistently use effective birth control ( e.g. , barrier method , oral contraceptive , intrauterine device , vasesctomy ) duration study participation approximately 8 week last dose GCSF . This necessary male female participant . 12 . For woman childbearing potential : 1 . Negative serum urine pregnancy test EXCLUSION CRITERIA 1 . Active uncontrolled infection time enrollment 2 . Current autoimmune condition require systemic ( oral , injection , parenteral ) therapy 3 . History vasculitis 4 . Current history hematologic lymphoid malignancy ( leukemia ) 5 . History splenomegaly current splenomegaly exam ultrasound ( ICL patient ) 6 . History hypersensitivity plerixafor and/or GCSF 7 . Systemic immunemodulatory agent within past 6 month 8 . Thrombocytopenia ( platelet &lt; 100,000 cells/microL ) 9 . Hepatitis B C seropositivity ( HBsAg positive antiHCV positive ) Need anticoagulant medication ( e.g. , warfarin , heparin ) , aspirin , clopidogrel , antiplatelet agent 10 . Creatinine clearance &lt; 50 mL/min include endstage renal disease require hemodialysis 11 . Symptomatic coronary artery disease 12 . Uncontrolled hypertension ( i.e. , rest systolic blood pressure &gt; 160 mmHg rest diastolic blood pressure &gt; 90 mmHg ) despite pharmacologic antihypertensive treatment confirm second blood pressure measurement do later day 13 . Cardiac , pulmonary , thyroid , renal , hepatic , neurological ( central peripheral ) disease disorder hemostasis require therapy consider significant protocol team 14 . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement 15 . Currently receive Lithium due contraindication coadministration GCSF lithium 16 . Past current psychiatric illness , opinion investigator , would interfere protocol adherence ability give write informed consent 17 . Any illness condition , opinion investigator , may substantially increase risk associate participation study compromise scientific objectives 18 . Participation clinical protocol include intervention , opinion investigator , may affect result current study 19 . Previous history anaphylactic reaction aspirin NSAIDS 20 . Female childbearing potential breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 26, 2017</verification_date>
	<keyword>Leukapheresis</keyword>
	<keyword>Progenitor Cells</keyword>
</DOC>